John Gerecitano Department of Oncology Memorial Sloan Kettering Cancer Center Biography Publications Institution JoVE Articles John Gerecitano has not added a biography. If you are John Gerecitano and would like to personalize this page please email our Author Liaison for assistance. Publications Heat Shock Protein 90 Inhibitors in the Treatment of Cancer: Current Status and Future Directions Expert Opinion on Investigational Drugs. May, 2014 | Pubmed ID: 24669860 A Phase 1/pharmacokinetic Study of Sunitinib in Combination with Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus-positive Patients with Cancer: AIDS Malignancy Consortium Trial AMC 061 Cancer. Apr, 2014 | Pubmed ID: 24474568 Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Feb, 2013 | Pubmed ID: 23248254 A Phase I Trial of the Kinesin Spindle Protein (Eg5) Inhibitor AZD4877 in Patients with Solid and Lymphoid Malignancies Investigational New Drugs. Apr, 2013 | Pubmed ID: 22615058 The Impact of Non-drug-related Toxicities on the Estimation of the Maximum Tolerated Dose in Phase I Trials Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Oct, 2012 | Pubmed ID: 22825582 Tissue Microarray Analysis Reveals Protein Expression Patterns and Potential Biomarkers of Clinical Benefit to Bortezomib in Relapsed/refractory Non-Hodgkin Lymphoma British Journal of Haematology. Jul, 2012 | Pubmed ID: 22533368 Augmenting Advance Care Planning in Poor Prognosis Cancer with a Video Decision Aid: a Preintervention-postintervention Study Cancer. Sep, 2012 | Pubmed ID: 22252775 Normalization of Pre-ASCT, FDG-PET Imaging with Second-line, Non-cross-resistant, Chemotherapy Programs Improves Event-free Survival in Patients with Hodgkin Lymphoma Blood. Feb, 2012 | Pubmed ID: 22184409 Phase I Trial of Weekly and Twice-weekly Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Relapsed or Refractory Non-Hodgkin Lymphoma Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Apr, 2011 | Pubmed ID: 21346146 Navitoclax, a Targeted High-affinity Inhibitor of BCL-2, in Lymphoid Malignancies: a Phase 1 Dose-escalation Study of Safety, Pharmacokinetics, Pharmacodynamics, and Antitumour Activity The Lancet. Oncology. Dec, 2010 | Pubmed ID: 21094089 Time to Treatment Response in Patients with Follicular Lymphoma Treated with Bortezomib is Longer Compared with Other Histologic Subtypes Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jan, 2010 | Pubmed ID: 20068103 A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Nov, 2009 | Pubmed ID: 19903785 The Future of Small Molecule Inhibitors in Lymphoma Current Oncology Reports. Sep, 2009 | Pubmed ID: 19679013 Phase 2 Study of Weekly Bortezomib in Mantle Cell and Follicular Lymphoma British Journal of Haematology. Sep, 2009 | Pubmed ID: 19624539 Drug-induced Cutaneous Vasculitis in Patients with Non-Hodgkin Lymphoma Treated with the Novel Proteasome Inhibitor Bortezomib: a Possible Surrogate Marker of Response? British Journal of Haematology. Aug, 2006 | Pubmed ID: 16882131 Novel Small Molecules in the Treatment of Lymphomas Cancer Treatment and Research. 2006 | Pubmed ID: 16704178 Treatment of Burkitt Lymphoma in Adults Expert Review of Anticancer Therapy. Mar, 2006 | Pubmed ID: 16503854 Homocysteine and Prothrombin Fragment 1+2 Levels in Patients with Veno-occlusive Disease After Stem Cell Transplantation Journal of Hematotherapy & Stem Cell Research. Apr, 2003 | Pubmed ID: 12804180 الاستجابة للعلاج خارج الحي من الأورام الابتدائية و / أو أسوشيتد الانبثاث لما قبل السريرية والسريرية التنمية من التداوي Adriana D. Corben*1, Mohammad M. Uddin*2, Brooke Crawford3, Mohammad Farooq4, Shanu Modi5, John Gerecitano5, Gabriela Chiosis2, Mary L. Alpaugh6 1Department of Pathology, Memorial Sloan Kettering Cancer Center, 2Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, 3Department of Radiology, Weill Cornell Medical College, 4Department of Medicine, Memorial Sloan Kettering Cancer Center, 5Department of Oncology, Memorial Sloan Kettering Cancer Center, 6Department of Surgery, Memorial Sloan Kettering Cancer Center JoVE 52157 의학
الاستجابة للعلاج خارج الحي من الأورام الابتدائية و / أو أسوشيتد الانبثاث لما قبل السريرية والسريرية التنمية من التداوي Adriana D. Corben*1, Mohammad M. Uddin*2, Brooke Crawford3, Mohammad Farooq4, Shanu Modi5, John Gerecitano5, Gabriela Chiosis2, Mary L. Alpaugh6 1Department of Pathology, Memorial Sloan Kettering Cancer Center, 2Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, 3Department of Radiology, Weill Cornell Medical College, 4Department of Medicine, Memorial Sloan Kettering Cancer Center, 5Department of Oncology, Memorial Sloan Kettering Cancer Center, 6Department of Surgery, Memorial Sloan Kettering Cancer Center JoVE 52157 의학